The following is a summary of “Association of Neurogranin and BACE1 With Clinical Cognitive Decline in Individuals With ...

Over a decade of clinical data, experience and know-how with lead polyclonal Treg cell therapy PTG-007 in type-1 diabetes will accelerate ...

A new study provides important insight into how amyloid-beta and tau proteins impact brain activity and possibly contribute to cognitive decline in Alzheimer's disease.

Amyloid-beta and tau proteins have long been associated with Alzheimer's disease. The pathological buildup of these proteins ...

HOOKIPA is very pleased to present a comprehensive preclinical proof-of-concept dataset related to HB-700, for the potential treatment of KRAS mutated cancers. KRAS mutations are most frequently found ...

Researchers from Rice University and Baylor College of Medicine have demonstrated a groundbreaking treatment that eradicates ...

ATCC will provide a broad range of in vivo and in vitro models, as well as specialized reagents, for use in infectious ...

Halia plans to advance HT-6184 into a Phase 2 clinical trial for obesity later this year. This trial will evaluate the safety, tolerability, and efficacy of HT-6184 in combination with semaglutide for ...

Shares of Novo Nordisk NVO lost 5.5% on Friday after the company announced top-line data from a mid-stage study evaluating ...

Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks’ proprietary antibody ...

(NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces the direct CNS anti-inflammatory ...